Chemical probes and inhibitors of bromodomains outside the BET family

Chemical probes and inhibitors of bromodomains outside the BET family

In the last five years, the development of inhibitors of bromodomains has emerged as an area of intensive worldwide research. Emerging evidence has implicated a number of non-BET bromodomains in the onset and progression of diseases such as cancer, HIV infection and inflammation. The development and...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Moustakim, M, Clark, P, Hay, D, Dixon, D, Brennan, P
Formáid:	Journal article
Foilsithe / Cruthaithe:	Royal Society of Chemistry 2016

Míreanna comhchosúla

Chemical probes for bromodomains outside the BET family
de réir: Brennan, P, et al.
Foilsithe / Cruthaithe: (2013)

Development of a potent and selective bromodomain chemical probe
de réir: Moustakim, M, et al.
Foilsithe / Cruthaithe: (2017)

Developing chemical probes for the BET bromodomains
de réir: Hewings, D, et al.
Foilsithe / Cruthaithe: (2012)

Development of chemical probes for the bromodomains of BRD7 and BRD9
de réir: Clark, P, et al.
Foilsithe / Cruthaithe: (2016)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
de réir: Hay, D, et al.
Foilsithe / Cruthaithe: (2013)

Discovery of a PCAF bromodomain chemical probe
de réir: Moustakim, M, et al.
Foilsithe / Cruthaithe: (2016)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
de réir: Filippakopoulos, P, et al.
Foilsithe / Cruthaithe: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
de réir: Filippakopoulos, P, et al.
Foilsithe / Cruthaithe: (2012)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
de réir: Picaud, S, et al.
Foilsithe / Cruthaithe: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
de réir: Picaud, S, et al.
Foilsithe / Cruthaithe: (2013)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
de réir: Jennings, L, et al.
Foilsithe / Cruthaithe: (2018)

Evaluation of linker length effects on a BET bromodomain probe
de réir: Traquete, R, et al.
Foilsithe / Cruthaithe: (2019)

Synthesis and biological investigation of (+)-JD1, an organometallic BET bromodomain inhibitor
de réir: Hassell-Hart, S, et al.
Foilsithe / Cruthaithe: (2019)

Selective inhibition of BET bromodomains.
de réir: Filippakopoulos, P, et al.
Foilsithe / Cruthaithe: (2010)

Discovery of BET bromodomain inhibitors and their role in target validation
de réir: Mueller, S, et al.
Foilsithe / Cruthaithe: (2014)

Selective inhibition of BET bromodomains.
de réir: Filippakopoulos, P, et al.
Foilsithe / Cruthaithe: (2010)

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
de réir: Picaud, S, et al.
Foilsithe / Cruthaithe: (2013)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
de réir: Noah R. Flynn, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Discovery of epigenetic probes against the bromodomain family of proteins
de réir: Clark, P
Foilsithe / Cruthaithe: (2015)

Design and synthesis of small molecule chemical probes for bromodomain-containing proteins.
de réir: Hay, D
Foilsithe / Cruthaithe: (2014)

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
de réir: Chaidos, A, et al.
Foilsithe / Cruthaithe: (2014)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
de réir: Kenneth K. W. To, et al.
Foilsithe / Cruthaithe: (2023-03-01)

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
de réir: Shu, Shaokun, et al.
Foilsithe / Cruthaithe: (2017)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
de réir: Lori, L, et al.
Foilsithe / Cruthaithe: (2016)

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
de réir: Alison M. Kurimchak, et al.
Foilsithe / Cruthaithe: (2016-08-01)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
de réir: Laura Lori, et al.
Foilsithe / Cruthaithe: (2016-01-01)

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
de réir: Sergey Karakashev, et al.
Foilsithe / Cruthaithe: (2017-12-01)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
de réir: Ian J. Groves, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Design of a chemical probe for the bromodomain and plant homeodomain finger-containing (BRPF) family of proteins
de réir: Igoe, N, et al.
Foilsithe / Cruthaithe: (2017)

Interactome rewiring following pharmacological targeting of BET bromodomains
de réir: Lambert, J-P, et al.
Foilsithe / Cruthaithe: (2018)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
de réir: Elisa Funck-Brentano, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
de réir: Martin V. Nguyen, et al.
Foilsithe / Cruthaithe: (2020-02-01)

BRD3 and BRD4 BET bromodomain proteins differentially regulate skeletal myogenesis
de réir: Roberts, T, et al.
Foilsithe / Cruthaithe: (2017)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
de réir: Flore Mietton, et al.
Foilsithe / Cruthaithe: (2017-05-01)

BET bromodomain proteins regulate enhancer function during adipogenesis
de réir: Brown, Jonathan D., et al.
Foilsithe / Cruthaithe: (2018)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
de réir: Jiacheng Lai, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
de réir: Cheng, Z, et al.
Foilsithe / Cruthaithe: (2013)

Inhibition of BET bromodomain targets genetically diverse glioblastoma.
de réir: Cheng, Z, et al.
Foilsithe / Cruthaithe: (2013)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
de réir: Wendy Mao, et al.
Foilsithe / Cruthaithe: (2019-10-01)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
de réir: Allison C. Ostriker, et al.
Foilsithe / Cruthaithe: (2015-11-01)